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Abstract
We describe eight human cases of Bordetella bronchiseptica infec-
tion and colonization over a 15-year period. Amongst the eight
patients, seven had signiﬁcant underlying disease. Cat exposure
was documented in three cases. Symptoms ranged from asymp-
tomatic carriage to severe pneumonia. We could not identify a
homogeneous pattern of clinical disease among symptomatic
patients. Although B. bronchiseptica infection remains a rare clini-
cal condition among humans, it should be considered as poten-
tially pathogenic when found in airways of immunocompromised
patients.
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Bordetella spp. are aerobic coccobacilli known to be present
in the upper respiratory tract of many animals [1]. B. bron-
chiseptica infections are uncommon in humans [2]. The
literature on this subject is subsequently poor. Two compre-
hensive reviews have been published in the last two decades.
The ﬁrst included 25 cases from 1911 to 1990 [1]. However,
the presence of B. bronchiseptica was microbiologically con-
ﬁrmed in only ten patients. The other study, published in
1995, included 52 patients but no details were provided
about the microbiological identiﬁcation of B. bronchiseptica
[3]. Another study published in 2005 focused on the patho-
genesis but gave little information on human infections [4].
Recently, several case reports addressed the problem in cys-
tic ﬁbrosis patients [5], HIV patients [2,6] or children with
lung transplants [7]. Facing this lack of recent information,
we decided to review all cases detected at our institution
from 1993 to 2008.
The present study was undertaken at the Geneva Univer-
sity Hospitals, a 2220-bed tertiary care centre. We per-
formed a retrospective case review approved by the
institutional ethics review board and based on computerized
laboratory log ﬁles, examining the pattern of disease caused
by B. bronchiseptica, addressing underlying conditions and
exposures, and examining antimicrobial treatment in relation
to patient outcome. To avoid misclassiﬁcation bias, we
included only patients with veriﬁed B. bronchiseptica isolates
because automated identiﬁcation systems can lead to misclas-
siﬁcation as Acinetobacter spp. or other nonfermentative
Gram-negative rods. Most cases were ﬁrst identiﬁed by API
20NE gallery or VITEK2 (bioMerieux SA, Marcy-l’Etoile,
France) phenotypic identiﬁcation systems, and then sup-
ported by a positive oxidase reaction. All available stored
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isolates (4/8) were veriﬁed as B. bronchiseptica by 16s rDNA
sequencing and a positive oxidase reaction, conﬁrming that
our phenotypic identiﬁcation was reliable. Because the
method of previous antimicrobial susceptibility testing (AST)
could not be veriﬁed in this retrospective study, we per-
formed new AST [MIC using the E-test (AB Biodisk, Solna,
Sweden)] on all available isolates, despite the absence of
CSLI guidelines for the E-test AST of B. bronchiseptica [8].
Therefore, E-tests were performed as previously recom-
mended [9]. Considering the fastidious character of the
microorganism, a second MIC determination was performed
at 48 h, but this did not reveal any relevant change in AST.
During a 15-year period, eight patients had conﬁrmed
B. bronchiseptica infection (n = 3), co-infection (n = 2) or col-
onization (n = 3). Table 1 summarizes the key features of
these cases. All specimens except one were retrieved from
the airways. Cases were equally distributed among gender
and age groups. Amongst the eight patients, seven had signiﬁ-
cant underlying disease, including four patients with severe
lung disease, two patients with AIDS and one patient with
autoimmune neutropenia. Three patients had documented
contact with cats prior to infection. In one case, the cat itself
had respiratory symptoms.
The disease pattern related to B. bronchiseptica was not
uniform. Except for one chronic obstructive pulmonary dis-
ease (COPD) patient who presented with colitis and septic
shock unrelated to B. bronchiseptica airway colonization,
three clinical presentations were observed: (i) two patients
were asymptomatic carriers of B. bronchiseptica; (ii) two
patients had symptoms of bronchitis; and (iii) three patients
presented with severe pneumonia. In two of these latter
cases, the pathogenic role of B. bronchiseptica was established
(e.g. lung abscess). The remaining patient with pneumonia
was co-infected with Pneumocystis jiroveci.
All available isolates (n = 4) were susceptible to amoxicil-
lin-clavulanate, piperacilin-tazobactam, imipenem, amikacin,
gentamicin, tobramycin, ciproﬂoxacin, and tigecyclin. Tri-
methoprim-sulfamethoxazole was susceptible in two of four
cases only and all four isolates were resistant to erythro-
mycin. Patients received various antibiotic treatment regi-
mens (Table 1). In two patients with pneumonia and one
patient with bronchitis, microbiological persistence of B. bron-
chiseptica was documented despite antimicrobial treatment.
Despite the inherent limitations of the retrospective
design of the present study and its small sample size, several
features emerge from this series of eight human B. bronchi-
septica cases, which is one of the most comprehensive in the
recent literature. Although we retrieved three cases in 2008,
the overall small number of cases does not enable us to con-
clude an increasing incidence of human B. bronchiseptica cases T
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because of possible random variation. The majority of our
patients presented with a signiﬁcant underlying disease,
mainly COPD or AIDS. The only patient without an underly-
ing condition presented an unusual location not previously
described: B. bronchiseptica was identiﬁed on the maternal
side of the placenta of an asymptomatic woman who was
admitted for delivery by Caesarean section. A laboratory
contamination could be reasonably excluded.
Our analysis conﬁrms the tropism of B. bronchiseptica for
the respiratory tract, leading to occasional upper airway col-
onization, as previously described [3]. The only case of death
observed was not caused by B. bronchiseptica because the
patient was diagnosed with septic shock due to colitis.
Immunocompromised patients who own cats should be
aware of this small but non-negligible threat of airway con-
tamination with B. bronchiseptica. Although an animal vaccine
for B. bronchiseptica exists [10], its efﬁcacy remains contro-
versial [4] and thus the vaccination of pets might not confer
protection. Because of cross immunity, immunocompromised
patients might, however, beneﬁt from B. pertusssis vaccina-
tion, as shown in a mouse model [11].
Different antibiotic regimens were administered to our
patients. This variety reﬂects the absence of reliable treat-
ment recommendations. As a consequence, we cannot pro-
vide any ﬁrm conclusion on the optimal therapeutic approach.
However, B. bronchiseptica are usually susceptible to anti-
pseudomonal penicillins, carbapenems, ﬂouroquinolones and
aminoglycosides, but not to erythromycin, in contrast to
other Bordetella species.
In summary, it remains difﬁcult to clearly establish the
pathogenic role of B. bronchiseptica in human disease as a
result of the rare occurrence and challenging microbiological
diagnosis. In the present study, we could reasonably establish
the microbiological identiﬁcation and pathogenic role of
B. bronchiseptica and therefore explore its related clinical
symptoms. On the basis of these cases, B. bronchiseptica
should be considered as potentially pathogenic when found
in the lower airways of immunocompromised patients.
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